Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

NCT04601181 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

B Cell Malignancy

Interventions

BIOLOGICAL: ThisCART22 cells injection

Sponsor

Fundamenta Therapeutics, Ltd.

Collaborators

[object Object]